Trials / Conditions / Solid Tumor, Unspecified, Adult

Solid Tumor, Unspecified, Adult

20 registered clinical trials studyying Solid Tumor, Unspecified, Adult — 11 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations NCT06895681	University of California, San Francisco	—
Enrolling By Invitation	A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Product NCT06885424	A2 Biotherapeutics Inc.	—
Recruiting	AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors NCT06911333	Avelos Therapeutics Inc.	Phase 1 / Phase 2
Recruiting	A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. NCT06883539	LaunXP Biomedical Co., Ltd.	Phase 1
Completed	The Safety and Dosimetry Study of 177Lu-LNC1004 Injection NCT05723640	Yantai LNC Biotechnology Singapore PTE. LTD.	Phase 1
Unknown	68 Gallium-Fibroblast Activating Protein Inhibitors-46 Positron Emission Tomography - Computerized Tomography NCT06136065	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	Phase 2
Recruiting	Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors NCT04643418	MegaPro Biomedical Co. Ltd.	Phase 1 / Phase 2
Terminated	A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors NCT04577963	Hutchmed	Phase 1 / Phase 2
Recruiting	Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related NCT04942717	Memorial Sloan Kettering Cancer Center	N/A
Completed	Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protei NCT04976803	Artios Pharma Ltd	—
Recruiting	Gustave Roussy Cancer Profiling NCT04932525	Gustave Roussy, Cancer Campus, Grand Paris	N/A
Recruiting	Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment NCT05695638	Morten Ladekarl	—
Recruiting	An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With NCT04443088	Shenzhen Ionova Life Sciences Co., Ltd.	Phase 1
Completed	Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors NCT04169321	Cytosite Biopharma Inc.	Phase 1
Completed	RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors NCT04252339	Hoffmann-La Roche	Phase 1
Recruiting	Psychotherapy Intervention for Latinos With Adv Cancer NCT04537936	Memorial Sloan Kettering Cancer Center	N/A
Completed	A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies NCT03628677	Arcus Biosciences, Inc.	Phase 1
Completed	Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair NCT03318445	Pamela Munster	Phase 1
Recruiting	Psychotherapy Intervention for Latinos With Advanced Cancer NCT04015609	Memorial Sloan Kettering Cancer Center	N/A
Approved For Marketing	Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusio NCT04100694	Merus B.V.	—